

TransEnterix, Inc. Reports Operating Results for the Fourth Quarter and Full Year 2013

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (OTCBB:TRXC), a medical device company that is pioneering the use of flexible instruments and robotics to improve how minimally invasive surgery is performed, today announced its operating and financial results for the fourth quarter and full year 2013, as well as its 2014 key objectives.

2013 Accomplishments

- Advanced the development of the SurgiBotTM system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field
- Conducted pre-clinical labs with key opinion leading surgeons using the SurgiBot
- Completed the merger with SafeStitch Medical, Inc.
- Closed a \$30.2 million equity financing
- Strengthened the management team, appointing Joseph Slattery as Executive Vice President & CFO

2014 Key Objectives

- Complete a pre-submission FDA filing for the SurgiBot™ system in the first quarter
- · Launch a flexible advanced energy device in the second quarter
- Begin SurgiBot first-in-man cases in third quarter
- Submit our SurgiBot regulatory filings in the fourth quarter
- Complete a financing in the first half of the year and uplist on the NYSE MKT

The Company has also scheduled an Investor & Analyst Event for April 3, 2014 in Salt Lake City.

"2013 was a transformational year for TransEnterix, as we made significant progress in the development of the SurgiBot and completed the SafeStitch merger," said Todd M. Pope, President and Chief Executive Officer of TransEnterix. "We are enthusiastic about the market opportunity for our SurgiBot system and look forward to bringing this innovative surgical robotic solution to the market."

Financial Results

Comparison of Selected Consolidated Financial Results (in thousands, except net loss per share)

Three Months Ended December 31, Full Year Ended December 31,

	<u>2013</u> <u>2012</u>		<u>2013</u>		<u>2012</u>		
Total revenue	\$ 219	\$	374	\$	1,431	\$	2,115
Net loss	\$ 8,031	\$	3,731	\$	28,358	\$	15,425
Net loss per share	\$ 0.04	\$	0.69	\$	0.45	\$	2.86
Weighted average common shares	187,173		5,391		63,655		5,391

Revenue was \$219,000 in the fourth quarter of 2013, representing a 41% decrease from revenue of \$374,000 in the fourth quarter of 2012. The decrease in revenue was primarily due to lower sales volumes of the SPIDER® Surgical System as a result of the reduction in our U.S. sales force headcount. TransEnterix has chosen to focus resources on the development of the SurgiBot system and away from continued investment in sales and marketing of the SPIDER System.

Research and development expenses were \$4.8 million in the fourth quarter of 2013, compared with \$1.7 million in the fourth quarter of 2012. The increase was largely attributable to higher personnel-related expenses as we increased headcount in our research and development and regulatory functions and an increase in other expenses related to product development of our SurgiBot.

Sales and marketing expenses for the fourth quarter of 2013 were \$453,000 compared to \$732,000 in the fourth quarter of 2012. The decrease was primarily related to lower personnel-related costs and decreased travel related expenses as we reduced our direct sales and marketing personnel and lowered expenditures for marketing clinical studies, demonstration product, tradeshows and other marketing expenses.

General and Administrative for the fourth quarter of 2013 were \$1.6 million compared to \$0.6 million in the fourth quarter of 2012. The increase was primarily due to higher personnel costs, greater costs associated with stock based compensation, and increased costs associated with being a public company.

Net loss in the fourth quarter of 2013 was \$8.0 million compared to a net loss of \$3.7 million in the fourth quarter of 2012. Net loss per common share was \$0.04 in the fourth quarter of 2013 based on 187.2 million weighted average common shares outstanding compared to a net loss per share of \$0.69 in the fourth quarter of 2012 based on 5.4 million weighted average common shares outstanding.

Cash, cash equivalents and short term investments were \$16.2 million as of December 31, 2013.

Conference Call

TransEnterix, Inc. will host a conference call on Wednesday, March 5, 2014 at 8:00 am ET to discuss its fourth quarter and full year 2013 operating and financial results. To listen to the conference call on your telephone, please dial (855) 469-0612 for domestic callers or (484) 756-4268 for international callers ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio webcast or the archived recording, use the following link http://ir.transenterix.com/events.cfm.

Financial Statements

On September 3, 2013, SafeStitch Medical, Inc. (now TransEnterix, Inc.) and TransEnterix Surgical, Inc., formerly known as TransEnterix, Inc., consummated a merger transaction (the "Reverse Merger") whereby TransEnterix Surgical, Inc. merged with a merger subsidiary of SafeStitch Medical, Inc., with TransEnterix Surgical, Inc. as the surviving entity in the merger. As a result of the merger, TransEnterix Surgical, Inc. became a wholly owned subsidiary of SafeStitch Medical, Inc. On December 6, 2013, SafeStitch Medical, Inc. changed its corporate name to TransEnterix, Inc.

The Reverse Merger has been accounted for as a reverse acquisition under which TransEnterix Surgical, Inc. was considered the acquirer of SafeStitch Medical, Inc. As such, the financial statements of TransEnterix Surgical, Inc. are treated as the historical financial statements of the combined company, with the results of SafeStitch Medical, Inc. being included from September 3, 2013.

As a result of the Reverse Merger with SafeStitch Medical, Inc., historical common stock amounts and additional paid in capital have been retroactively adjusted.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of flexible instruments and robotics to improve minimally invasive surgery. The company is focused on the development and commercialization of SurgiBot[™], a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field. For more information, visit the company's website at <u>www.transenterix.com</u>.

Forward Looking Statements

This press release includes statements relating to the SurgiBot system and our current regulatory and commercialization plans for the system. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations and include whether we will complete a pre-submission FDA filing of the SurgiBot[™] system in the 2014 first quarter, whether we will launch a flexible advanced energy device in the 2014 secon quarter, whether we will begin SurgiBot first-in-man cases in the 2014 third quarter, whether we submit our SurgiBot system regulatory filings in the 2014 fourth quarter, whether we can complete a financing in first half of 2014 and uplist to the NYSE MKT, and whether we will be able to bring the SurgiBot system to the market. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the SurgiBot system's 510(k) application(s) will be cleared by the U.S. FDA, whether the combined company will be successful in 2014 and beyond, the pace of adoption of our product technology by surgeons, the outcome of coverage and reimbursement decisions by the government and third party payors, the success and market opportunity of our continuing and new product development efforts, including the SurgiBot system, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2013, the Form 8-K filed on September 6, 2013 and subsequent SEC reports. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release. We undertake no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

TransEnterix, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except net loss per share)

	Decem	nths ended ber 31,	Year ended December 31,		
	2013 2012		2013	2012	
	```	(Unaudited)			
Sales	\$ 219	\$ 374	\$ 1,431	\$ 2,115	
Operating Expenses					
Cost of goods sold	714	955	4,810	4,420	
Research and development	4,845		12,700	6,283	
Sales and marketing	453			3,723	
General and administrative	1,556	587		2,763	
Loss on disposal of property and equipment	450	-	450	-	
Merger expenses	20	-	2,911	-	
Total Operating Expenses	8,038	4,005	27,035	17,189	
Operating Loss	(7,819)	(3,631)	(25,604)	(15,074)	
Other (Expense) Income Remeasurement of fair value of preferred stock warrant liability Interest expense, net	(212)	- (100)	(1,800) (954)	(351)	
Total Other (Expense) Income, net	(212)	(100)	(2,754)	(351)	
Net Loss	\$ (8,031)	\$ (3,731)	<u>\$(28,358)</u>	<u>\$(15,425)</u>	
Other comprehensive income (loss)					
Comprehensive loss	\$ (8,031)	\$ (3,731)	<u>\$(28,358)</u>	\$(15,425)	
Net loss per share - basic and diluted	\$ (0.04)	\$ (0.69)	<u>\$ (0.45)</u>	<u>\$ (2.86)</u>	
Weighted average common shares outstanding - basic and diluted	187,173	5,391	63,655	5,391	

#### TransEnterix, Inc. Consolidated Balance Sheets (in thousands, except share amounts)

Short-term investments   6,191   907     Accounts receivable, net   188   536     Interest receivable   68   16     Inventory, net   701   1,382     Other current assets   533   235     Total Current Assets   17,755   11,972     Restricted cash   375   375     Property and equipment, net   1,864   1,767     Intelectual property, net   2,741   3,241     Total cannes, net   10   -     Goodwill   93,842   -     Other current isbilities   \$   116,714   \$     Accrued expenses   1,406   538   -     Note payable - current portion   3,879   1,519     Total Current Labilities   -   109   -     Note payable - less current portion   4,602   8,481     Total Current Labilities   11,691   11,168     Commitments and Contingencies   -   109     Note payable - less current portion   4,602   8,481     Total	Current Assets Cash and cash equivalents	\$	10,014	\$	8,896
Interest receivable6816Inventory, net7011,382Other current assets593236Total Current Assets17,75511,972Restricted cash375375Property and equipment, net1,8641,767Intellectual property, net2,7413,241Trade names, net10-Goodwill93,842-Ottal Assets\$ 116,714\$ 17,560Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)-Current Liabilities\$ 1,804\$ 521Accrued expenses\$ 1,804\$ 521Long Term Liabilities7,0892,578Long Term Liabilities11,69111,691Preferred Stock warrant liability-109Note payable - less current portion4,6028,481Total Liabilities11,69111,69111,691Commitments and Contingencies11,69111,69111,691Redeemable Convertible Preferred Stock, \$0,001 par value, 5,734,402 shares authorized; and 14,89,972 shares issued and outstanding at December 31, 2012 series B. Redeemable Convertible Preferred Stock, \$0,001 par value, 48,454,545 shares authorized; and 45,989,220 shares issued and outstanding at December 31, 2012 	•	Ŷ		Ψ	
Inventory, net   701   1.822     Other current assets   593   235     Total Current Assets   17,755   11,972     Restricted cash   375   375     Property and equipment, net   1.864   1,872     Intellectual property, net   2,741   3,241     Other long term assets   10   -     Goodwill   03.842   -     Other long term assets   127   205     Total Assets   \$   116,714   \$     Accounts payable   \$   1.804   \$     Accounts payable   3.879   1.519   1.519     Total Liabilities   7,038   2.578   1.602   8.481     Total Liabilities   11,691   11,681   11,691   11,681     Commitments and Contingencies   11,691   11,681   11,691   11,681     Commitments and Contingencies   3.001 par value, 5,734,402 shares authorized; and 5.692,603   40,016   18,855     Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5.693,6120 shares issued an	Accounts receivable, net		188		536
Other current assets   593   2235     Total Current Assets   17,755   11,972     Restricted cash   375   375     Property and equipment, net   1,864   1,767     Intellectual property, net   2,741   3,241     Tade names, net   0   -     Goodwill   93,842   -     Other long term assets   \$116,714   \$17,755     Total Assets   \$116,714   \$17,560     Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)   Current Liabilities     Accrued expenses   \$18,044   \$521     Note payable - current portion   3,879   1,519     Total Current Liabilities   7,089   2,578     Long Term Liabilities   11,691   11,168     Commitments and Contingencies   11,691   11,691     Redeemable Convertible Preferred Stock   \$0.001 par value, 5,734,402 shares authorized; and 5,486,261 shares issued and outstanding at December 31, 2012   40,016     Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,486,201 shares issued and outstanding at December 31, 2012   40,016 <td></td> <td></td> <td></td> <td></td> <td>-</td>					-
Total Current Assets17,75511,972Restricted cash375375Property and equipment, net1.8641,767Intellectual property, net2,7413,241Trade names, net0-Goodwill93,842-Other long term assets127205Total Assets\$116,714\$Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)-Current Liabilities\$1.804\$Accounts payable\$1.804\$Accounts payable - current portion3.8791.519Total Current Liabilities7,0892,578Long Terrn Liabilities7,0892,578Long Terrn Liabilities11,69111,168Prefered stock warrant liability-109Note payable - current portion4.6028.481Total Liabilities11,69111,168Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 201240,016Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 43,454,545 shares authorized; and 45,989,203 shares issued and outstanding at December 31, 201240,016Series B H Redeemable Convertible Preferred Stock, \$0.001 par value, 43,454,545 shares authorized; and 5,696,203 shares issued and outstanding at December 31, 201240,016Stockholders' Equity (Deficit)Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares	•				
Restricted cash 375 375   Property and equipment, net 1,864 1,767   Intellectual property, net 2,741 3,241   Trade names, net 0 32,42   Codwill 93,842 -   Other long term assets 127 205   Total Assets \$ 116,714 \$ 17,560   Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit) Current Liabilities   Accrued expenses \$ 1,804 \$ 521   Accrued expenses \$ 1,804 \$ 521   Note payable - current portion 3,879 1,519   Total Current Liabilities 7,089 2,578   Long Term Liabilities 11,691 11,168   Commitments and Contingencies 11,691 11,168   Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,962,261 shares issued and outstanding at December 31, 2012 - 19,885   Series B. Redeemable Convertible Preferred Stock, \$0.001 par value, 4,845,454 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 2012 - 15,104   Stockholders' Equity (Deficit) Common stock \$0,000 par value, 750,000,0000 and 130,322,900 shares authorized at Decembe					
Property and equipment, net1.8641.767Intellectual property, net2,7413,241Trade names, net0-Goodwill93,842-Other long term assets127205Total Assets\$116,714\$Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)-Current Liabilities\$1,804\$Accrued expenses1,406533Note payable - current portion3,8791,519Total Current Liabilities7,0892,578Long Term Liabilities7,0892,578Long Term Liabilities11,69111,691Preferred Stock warant liability-109Note payable - less current portion4,6028,481Total Liabilities11,69111,69111,688Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 1,489,972 shares issued and outstanding at December 31, 2012-19,885Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 4,543,545 shares authorized; and 45,994,203 shares issued and outstanding at December 31, 2012-15,104Stockholders' Equity (Deficit)12,2445Common stock \$0.001 par value, 750,000,000 and 130, 322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively2445Stockholders' Equity (Deficit)12,885Common stock \$0.001 par value, 750,000,	Total Current Assets		17,755		11,972
Property and equipment, net1.8641.767Intellectual property, net2,7413,241Trade names, net0-Goodwill93,842-Other long term assets127205Total Assets\$116,714\$Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)-Current Liabilities\$1,804\$Accrued expenses1,406533Note payable - current portion3,8791,519Total Current Liabilities7,0892,578Long Term Liabilities7,0892,578Long Term Liabilities11,69111,691Preferred Stock warant liability-109Note payable - less current portion4,6028,481Total Liabilities11,69111,69111,688Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 1,489,972 shares issued and outstanding at December 31, 2012-19,885Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 4,543,545 shares authorized; and 45,994,203 shares issued and outstanding at December 31, 2012-15,104Stockholders' Equity (Deficit)12,2445Common stock \$0.001 par value, 750,000,000 and 130, 322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively2445Stockholders' Equity (Deficit)12,885Common stock \$0.001 par value, 750,000,	Restricted cash		375		375
Trade names, net10Goodwill93,842Other long term assets127Total Assets\$ 116,714 \$ 17,560Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)Current LiabilitiesAccounts payable\$ 1,804 \$ 521Accounds payable - current portion3,879Total Current Liabilities7,089Preferred stock warrant liability- 109Note payable - less current portion4,602Redeemable Convertible Preferred Stock, \$0,001 par value, 5,734,402 sharesauthorized; and 5,682,681 shares issued and outstanding at December 31, 2012- 19,885Series & Redeemable Convertible Preferred Stock, \$0,001 par value, 5,734,402 sharesauthorized; and 45,998,220 shares issued and outstanding at December 31, 2012- 40,016Series B - Redeemable Convertible Preferred Stock, \$0,001 par value, 48,454 sharesauthorized; and 45,998,220 shares issued and outstanding at December 31, 2012- 15,104Stockholders' Equity (Deficit)- 203,043 1,288Accumulated deficit(98,264)Common stock \$0,001 par value, 71, 2013 and December 31, 2012, respectively244Additional paid-in capital(99,906)Total Stockholders' Equity (Deficit)- 105,023Cotal Stockholders' Equity (Deficit)- 105,023Total Stockholders' Equity (Deficit)- 105,023Common stock \$0,001 par value, 71, 2013 and December 31, 2012, respectively2445- 5,03,0431,288Accumulated deficit(99,906)Total Stockholders' Equity (Deficit					
Goodwill Other long term assets93,842 127-Total Assets127205S116,714\$Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)-Current LiabilitiesAccounts payable\$Accrued expenses1,406538Note payable - current portion3,879Total Current Liabilities-Preferred stock warrant liability-Note payable - less current portion4,602Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,66,261 shares issued and outstanding at December 31, 2012-Stockholders' Equity (Deficit)-Commit and S0,98,220 shares issued and outstanding at December 31, 2012-Stockholders' Equity (Deficit)-Common stock \$0.001 par value, 5,734,402 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 2012-Stockholders' Equity (Deficit)-Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2012, respectively, 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively244 203,043Stockholders' Equity (Deficit)-203,0431,288Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2012, respectively, 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively, 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively, 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectivel	Intellectual property, net		2,741		3,241
Other long term assets127205Total Assets\$ 116,714\$ 17,560Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)Current Liabilities\$ 1,804\$ 521Accounts payable\$ 1,804\$ 521Account spayable - current portion3,8791,519Total Current Liabilities7,0892,578Long Term Liabilities7,0892,578Dreferred stock warrant liability- 109Note payable - less current portion4,602Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 2012- 19,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012- 40,016Series B -1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012- 15,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively, 2445Additional paid-in capital Accumuted deficit203,0431,288Cottal Stockholders' Equity (Deficit)- 105,023(68,613)					-
Total Assets\$ 116,714 \$ 17,560Liabilities\$ 116,714 \$ 17,560LiabilitiesAccounts payableAccrued expenses\$ 1,804 \$ 521Accrued expenses1,406 538Note payable - current portion1,406 538Total Current Liabilities7,089 2,578Long Term Liabilities- 109Note payable - less current portion4,602 8,481Total Liabilities11,691 11,691Preferred stock warrant liability- 109Note payable - less current portion4,602 8,481Total Liabilities11,691 11,168Commitments and Contingencies11,691 11,168Redeemable Convertible Preferred Stock5,734,402 sharesSeries A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares- 19,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares- 10,168Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares- 15,104Stockholders' Equity (Deficit)- 15,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244, 207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit20,43 1,288Total Stockholders' Equity (Deficit)- 105,023 (68,613)					-
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)   Current Liabilities   Accounts payable   Current Liabilities   Preferred stock warrant liability   Note payable - less current portion   4.602   8.481   Total Liabilities   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691   11,691	•	<u>¢</u>		¢	
Current Liabilities\$ 1,804 \$ 521Accounts payable\$ 1,804 \$ 521Accrued expenses\$ 1,406Note payable - current portion3,879Total Current Liabilities7,089Preferred stock warrant liability- 109Note payable - less current portion4,602Redeemable Convertible Preferred StockSeries A Redeemable Convertible Preferred Stock, \$0,001 par value, 5,734,402 sharesauthorized; and 5,696,261 shares issued and outstanding at December 31, 2012Series B Redeemable Convertible Preferred Stock, \$0,001 par value, 11,504,298 sharesauthorized; and 11,489,972 shares issued and outstanding at December 31, 2012Series B Redeemable Convertible Preferred Stock, \$0,001 par value, 48,454,545 sharesauthorized; and 45,998,220 shares issued and outstanding at December 31, 2012Stockholders' Equity (Deficit)Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectivelyAdditional paid-in capital Accumulated deficitAccumulated deficitTotal Stockholders' Equity (Deficit)Total Stockholders' Equity (Deficit)Total Stockholders' Equity (Deficit)	TOTAL ASSETS	φ	110,714	φ	17,300
Accounts payable\$1,804\$521Accrued expenses1,406538Note payable - current portion3,8791,519Total Current Liabilities7,0892,578Long Term Liabilities7,0892,578Preferred stock warrant liability-109Note payable - less current portion4,6028,481Total Liabilities11,69111,168Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock50,001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 2012-19,885Series B Redeemable Convertible Preferred Stock, \$0,001 par value, 11,504,298 shares authorized; and 14,489,972 shares issued and outstanding at December 31, 2012-40,016Series B-1 Redeemable Convertible Preferred Stock, \$0,001 par value, 48,454,545 shares authorized; and 45,988,220 shares issued and outstanding at December 31, 2012-15,104Stockholders' Equity (Deficit)Common stock \$0,001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2013 and December 31, 2012, respectively: 244, 207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively2445Additional paid-in capital Accumulated deficit(68,906)(69,906)Total Stockholders' Equity (Deficit)105,023(68,613)					
Accrued expenses1,406538Note payable - current portion3,8791,519Total Current Liabilities7,0892,578Long Term Liabilities7,0892,578Dy Note payable - less current portion4,6028,481Total Liabilities11,69111,169Total Liabilities11,69111,169Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock5734,402 sharesSeries A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares19,885authorized; and 1,489,972 shares issued and outstanding at December 31, 201219,885Series B. Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares40,016Series B. Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares40,016Series B. 1 Redeemable Convertible Preferred Stock, \$0.001 par value, 13,201215,104Stockholders' Equity (Deficit)Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 201215,104Stockholders' Equity (Deficit)203,0431,288Accumulated deficit(98,264)(69,906)Total Stockholders' Equity (Deficit)105,023(68,613)		¢	1 804	¢	521
Note payable - current portion3.8791,519Total Current Liabilities7,0892,578Long Term Liabilities7,0892,578Note payable - less current portion4,6028,481Total Liabilities11,69111,168Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 1,489,972 shares issued and outstanding at December 31, 201219,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 14,545,454 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201240,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 201215,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244, 207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively; 2445Additional paid-in capital Accumulated deficit(69,906)Total Stockholders' Equity (Deficit)(09,203) (68,613)Total Stockholders' Equity (Deficit)(05,023) (68,613)		φ		ψ	
Total Current Liabilities7,0892,578Long Term Liabilities7,0892,578Preferred stock warrant liability-109Note payable - less current portion4,6028,481Total Liabilities11,69111,168Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 2012-19,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 14,89,972 shares issued and outstanding at December 31, 2012-40,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012-15,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244, 207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively; 2445203,0431,288Additional paid-in capital Accumulated deficit105,023(68,613)Total Stockholders' Equity (Deficit)Total Stockholders' Equity (Deficit)Total Stockholders' Equity (Deficit)Total Stockholders' Equity (Deficit)Total Stockholders' Equity (Defic	•				
Preferred stock warrant liability-109Note payable - less current portion4,6028,481Total Liabilities11,69111,168Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 2012 Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 2012 Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012 Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244, 207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit244 (69,306)Total Stockholders' Equity (Deficit)105,023(68,613)			7,089		
Preferred stock warrant liability-109Note payable - less current portion4,6028,481Total Liabilities11,69111,168Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 2012 Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 2012 Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012 Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244, 207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit244 (69,306)Total Stockholders' Equity (Deficit)105,023(68,613)					
Note payable - less current portion4,6028,481Total Liabilities11,69111,168Commitments and Contingencies11,69111,168Redeemable Convertible Preferred Stock Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 201219,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201240,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 201215,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit2445Total Stockholders' Equity (Deficit)105,023(68,613)	•				400
Total Liabilities11,69111,168Commitments and ContingenciesRedeemable Convertible Preferred Stock Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 201219,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201219,885Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 201240,016Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit244 (98,264) (69,906)Total Stockholders' Equity (Deficit)105,023(68,613)			-		
Commitments and ContingenciesRedeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 201219,885Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201219,885Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201240,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 201215,104Stockholders' Equity (Deficit)Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectivelyAdditional paid-in capital Accumulated deficit(98,264)(69,906)Total Stockholders' Equity (Deficit)105,023(68,613)	Note payable - less current portion		4,002		0,401
Redeemable Convertible Preferred StockSeries A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 201219,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201240,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 201215,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit2445Total Stockholders' Equity (Deficit)105,023(68,613)	Total Liabilities		11,691		11,168
Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 201219,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201240,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 201215,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit2445Total Stockholders' Equity (Deficit)105,023(68,613)	Commitments and Contingencies				
Series A Redeemable Convertible Preferred Stock, \$0.001 par value, 5,734,402 shares authorized; and 5,696,261 shares issued and outstanding at December 31, 201219,885Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201240,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 201215,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit2445Total Stockholders' Equity (Deficit)105,023(68,613)	Redeemable Convertible Preferred Stock				
Series B Redeemable Convertible Preferred Stock, \$0.001 par value, 11,504,298 shares authorized; and 11,489,972 shares issued and outstanding at December 31, 201240,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012-40,016Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2012, respectively Additional paid-in capital Accumulated deficit2445Total Stockholders' Equity (Deficit)105,023(68,613)					
authorized; and 11,489,972 shares issued and outstanding at December 31, 2012-40,016Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012-15,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2013, and December 31, 2012, respectively2445Additional paid-in capital Accumulated deficit203,0431,288 (69,906)Total Stockholders' Equity (Deficit)105,023(68,613)			-		19,885
Series B-1 Redeemable Convertible Preferred Stock, \$0.001 par value, 48,454,545 shares authorized; and 45,998,220 shares issued and outstanding at December 31, 2012-15,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively Additional paid-in capital Accumulated deficit244 203,043 (69,906)Total Stockholders' Equity (Deficit)105,023 (68,613)					40.016
authorized; and 45,998,220 shares issued and outstanding at December 31, 2012-15,104Stockholders' Equity (Deficit) Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively Additional paid-in capital Accumulated deficit2445Total Stockholders' Equity (Deficit)105,023(68,613)			-		40,010
Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively2445Additional paid-in capital Accumulated deficit203,0431,288 (69,906)Total Stockholders' Equity (Deficit)105,023(68,613)			-		15,104
Common stock \$0.001 par value, 750,000,000 and 130,322,900 shares authorized at December 31, 2013 and December 31, 2012, respectively; 244,207,733 and 5,391,095 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively2445Additional paid-in capital Accumulated deficit203,0431,288 (69,906)Total Stockholders' Equity (Deficit)105,023(68,613)	Stockholders' Equity (Deficit)				
shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively2445Additional paid-in capital203,0431,288Accumulated deficit(98,264)(69,906)Total Stockholders' Equity (Deficit)105,023(68,613)					
Additional paid-in capital 203,043 1,288   Accumulated deficit (98,264) (69,906)   Total Stockholders' Equity (Deficit) 105,023 (68,613)					
Accumulated deficit   (98,264)   (69,906)     Total Stockholders' Equity (Deficit)   105,023   (68,613)					
Total Stockholders' Equity (Deficit)   105,023   (68,613)					
			(90,204)		(09,900)
Total Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit) <u>\$ 116,714</u> <u>\$ 17,560</u>	Total Stockholders' Equity (Deficit)		105,023		(68,613)
	Total Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)	\$	116,714	\$	17,560

Westwicke Partners Mark Klausner, 443-213-0501 transenterix@westwicke.com News Provided by Acquire Media